Coronavirus disease 2019 (COVID-19) is a fast-moving pandemic affecting almost the whole of the world. The disease is rapidly rising with a sharply increasing curve. Since this is a novel virus and its properties are not well understood, investigating the pathophysiology, diagnostic values, and immune response of the body is the need of the hour today. The clinical practice needs to be put in the right direction while following the right laboratory and management strategies. Analysis by molecular diagnostic tests and immunodiagnostic tests are complementary to each other in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The role of antibody estimation in COVID-19 infection needs to be explored so that it can be used in understanding the seroprevalence, surveillance, and containment policies. Its utility in ascertaining the asymptomatic patients and susceptible individuals cannot be denied. It is yet to be confirmed that antibody response confers immunity to SARS-CoV-2. The methodology of estimation of antibodies is also an important aspect as sensitivity and specificity play an important role.
Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395(10223):514–523. DOI: 10.1016/S0140-6736(20)30154-9.
An overview of the rapid test situation for COVID-19 diagnosis in the EU/EEA. European Centre for Disease Prevention and Control. https://www.ecdc.europa.eu/sites/default/files/documents/Overviewrapid-test-situation-for-COVID-19-diagnosis-EU-EEA.pdf. Published April 1, 2020. Accessed April 15, 2020.
World Health Organization, Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. https://apps.who.int/iris/bitstream/handle/10665/331501/WHOCOVID-19-laboratory-2020.5-eng.pdf. Published March 19, 2020. Accessed April 15, 2020.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Interim Guidance: Healthcare Professionals 2019-nCoV. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinicalcriteria.html. Published March 14, 2020. Accessed April 15, 2020.
Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12(3):E254. DOI: 10.3390/v12030254.
Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24(6):490–502. DOI: 10.1016/j.tim.2016.03.003.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733. DOI: 10.1056/NEJMoa2001017.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. How Coronavirus Spreads. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/howcovid-spreads.html. Published April 2, 2020. Accessed April 15, 2020.
World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. https://www.who.int/news-room/commentaries/detail/modes-oftransmission-of-virus-causing-covid-19-implications-for-ipc-precautionrecommendations. Published March 29, 2020. Accessed April 15, 2020.
Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104(3):246–251. DOI: 10.1016/j.jhin.2020.01.022.
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020(4):1–8. DOI: 10.1038/s41564-020-0688-y.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8. DOI: 10.1016/j.cell.2020.02.052.
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 74. https://www.who.int/docs/defaultsource/coronaviruse/situationreports/20200403-sitrep-74-covid-19-mp.pdf. Published April 3, 2020. Accessed April 15, 2020.
Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172(9):577–582. DOI: 10.7326/M20-0504.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Symptoms of Coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/symptomstesting/symptoms.html. Published March 20, 2020. Accessed April 15, 2020.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–1069. DOI: 10.1001/jama.2020.1585.
Woo PCY, Lau SKP, Wong BHL, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol 2004;11(4):665–668. DOI: 10.1128/CDLI.11.4.665-668.2004.
Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. Eur Resp J 2020(2):2000763. DOI: 10.1183/13993003.00763-2020.
Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 2007;357(11):1162–1163. DOI: 10.1056/NEJMc070348.
Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 2020;584(7819):115–119. DOI: https://doi.org/10.1038/s41586-020-2380-z.
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020;323(22):2249–2251 DOI: 10.1001/jama.2020.8259.
Liu W, Liu L, Kou G, et al. Evaluation of nucleocapsid and spike protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol 2020;58(6):00461-20. DOI: 10.1128/JCM.00461-20.
To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020;20(5):565–574. DOI: 10.1016/S1473-3099(20)30196-1.
Long Q, Deng H, Chen J, et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: The perspective application of serological tests in clinical practice. medRxiv 2020. DOI: https://doi.org/10.1101/2020.03.18.20038018.
Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020. ciaa344. DOI: 10.1093/cid/ciaa344.
Xiao DAT, Gao DC, Zhang DS. Profile of specific antibodies to SARSCoV-2: the first report. J Infect 2020;81(1):147–178. DOI: 10.1016/j.jinf.2020.03.012.
Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv 2020. DOI: https://doi.org/10.1101/2020.03.12.20035048.
Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581(7809):465–469. DOI: 10.1038/s41586-020-2196-x.
Tan W, Lu Y, Zhang J, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv 2020. preprint https://doi.org/10.1101/2020.03.24.20042382.
Okba N, Müller M, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv 2020. DOI: https://doi.org/10.1101/2020.03.18.20038059.
World Health Organization. Coronavirus disease (COVID-2019) R&D. https://www.who.int/blueprint/priority-diseases/key-action/novelcoronavirus/en/. Published April 11, 2020. Accessed April 15, 2020.
Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020;71(15):778–785. DOI: 10.1093/cid/ciaa310.
Kissler S, Tedijanto C, Lipsitch M, et al. Social distancing strategies for curbing the COVID-19 epidemic. medRxiv 2020. DOI: https://doi.org/10.1101/2020.03.22.20041079.
Patel R, Babady E, Theel ES, et al. Report from the american society for microbiology COVID-19 international summit, 23 march 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. mBio 2020;11(2):e00722-20. DOI: 10.1128/mBio.00722-20.
Johns Hopkins Bloomberg School of Public Health, Center for Health Security, Serology-based tests for COVID-19. Last Updated April 30, 2020. Available at: https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html.
Gronvall G, Connell N, Kobokovich A, et al., Developing a National Strategy for Serology (Antibody Testing) in the United States. The Johns Hopkins Center for Health Security, April 22, 2020. Available at: https://www.centerforhealthsecurity.org/our-work/publications/developing-a-national-strategy-for-serology-antibody-testing-in-the-US.
Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181(2):281–292.e6. DOI: 10.1016/j.cell.2020.02.058.
Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;63(3):457–460. DOI: https://doi.org/10.1007/s11427-020-1637-5.
Interim Guidelines for COVID-19 Antibody Testing. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. May 23, 2020.
Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26(6):845–848. DOI: 10.1038/s41591-020-0897-1.
Theel ES, Slev P, Wheeler S, et al. The role of antibody testing for SARS-CoV-2: is there one? J Clin Micro 2020(8). DOI: 10.1128/JCM. 00797-20.
Indian Council of Medical Research. Guidance on rapid antibody kits for COVID-19. https://www.icmr.gov.in/pdf/covid/kits/ELISA_CLIA_Kits_List_03062020.pdf. Published on 4th june 2020.